Objective: To clarify the effect of postmastectomy radiotherapy (PMRT) on pTN breast cancer patients with different molecular subtypes.
Methods: We retrospectively analyzed the data of 5442 patients with pTN breast cancer treated using modified radical mastectomy in 11 hospitals in China. Univariate, multivariate, and propensity score matching (PSM) analyses were used to evaluate the effect of PMRT on locoregional recurrence (LRR).
Results: With a median follow-up duration of 63.8 months, the 5-year LRR rates were 4.0% and 7.7% among patients treated with and without PMRT, respectively (p < 0.001). PMRT was independently associated with reduced LRR after adjustments for confounders (p < 0.001). After grouping the patients according to the molecular subtype of cancer and conducting PSM, we found that the 5-year LRR rates among patients treated with and without PMRT (in that order) were as follows: luminal HER2-negative cancer, 1.9% and 6.5% (p < 0.001); luminal HER2-positive cancer, 3.8% and 13.7% (p = 0.041); HER2-overexpressing cancer, 10.2% and 15.5% (p = 0.236); and triple-negative cancer, 4.6% and 15.9% (p = 0.002). Among patients with HER2-overexpressing and triple-negative cancers, the LRR hazard rate displayed a dominant early peak, and was extremely low after 5 years. However, patients with luminal cancer continued to have a long-lasting high annual LRR hazard rate during follow-up.
Conclusion: PMRT significantly reduced the LRR risk in patients with pTN luminal and triple-negative breast cancers, but had no effect on the LRR risk in patients with HER2-overexpressing cancer. Patients with different molecular subtypes displayed different annual LRR patterns, and the late recurrence of the luminal subtype suggests the necessity of long-term follow-up to evaluate the efficacy of PMRT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695355 | PMC |
| http://dx.doi.org/10.1016/j.breast.2021.12.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacologic Induction of ERα SUMOylation Disrupts Its Chromatin Binding.
ACS Chem Biol
November 2024
National Institute of Biological Sciences, Beijing 102206, China.
Article Synopsis
- Estrogen receptor α (ERα)-positive breast cancer is commonly treated with ERα inhibitors like SERMs and SERDs, but their specific effects are not fully understood.
- In this research, scientists used methods such as mass spectrometry to show that the drug fulvestrant enhances the connection between ERα and specific proteins (SUMO E3 ligases), leading to a modification process called SUMOylation.
- This SUMOylation reduces ERα's ability to bind to DNA in chromatin and is also seen in other drugs like raloxifene and elacestrant, suggesting a new way to disrupt ERα functions for better cancer treatments.
Effects of pleiotrophin (PTN) on the FAK inhibitor Y15 in breast cancer cells.
Int J Biol Macromol
September 2024
The Center for Combinatorial Chemistry and Drug Discovery, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin, People's Republic of China. Electronic address:
Overexpression of PTN (Pleiotrophin) in breast cancer cells stimulates breast cell proliferation and anti-apoptosis via the FAK/Src signaling pathway.1,2,4,5-Benzenetetramine tetrahydrochloride (CHClN) known as Y15 is an inhibitor that specifically blocks phosphorylation of Y397-FAK and total FAK phosphorylation. The exogenous PTN protein was induced to be expressed by a prokaryotic expression strain.
View Article and Find Full Text PDFSingle-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma.
J Zhejiang Univ Sci B
August 2024
Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Objectives: The present study used single-cell RNA sequencing (scRNA-seq) to characterize the cellular composition of ovarian carcinosarcoma (OCS) and identify its molecular characteristics.
Methods: scRNA-seq was performed in resected primary OCS for an in-depth analysis of tumor cells and the tumor microenvironment. Immunohistochemistry staining was used for validation.
Unraveling the metastatic niche in breast cancer bone metastasis through single-cell RNA sequencing.
Clin Transl Oncol
July 2024
Department of Breast Oncology Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, Guangdong, China.
Purpose: Breast cancer (BRCA) is characterized by a unique metastatic pattern, often presenting with bone metastasis (BoM), posing significant clinical challenges. Through the study of the immune microenvironment in BRCA BoM offer perspectives for therapeutic interventions targeting this specific metastatic manifestation of BRCA.
Methods: This study employs single-cell RNA sequencing and TCGA data analysis to comprehensively compare primary tumors (PT), lymph node metastasis (LN), and BoM.
Pleiotrophin serum level and metastasis occurrence in breast cancer patients.
Breast Dis
May 2024
Department of Surgery, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.
Background: Breast cancer (BC) cases in Makassar, Indonesia, are on the rise, with 2723 cases recorded in 2018. Tumor cells in the blood indicate metastasis, emphasizing the need for early diagnosis and monitoring. Pleiotrophin (PTN) is associated with various human malignancies, and recent studies suggest a correlation between PTN expression and advanced BC stages; therefore, PTN could serve as an independent predictor of metastasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!